

Supplementary Table 4. Changes from baseline to week 24 in PDQ-39 subdomain scores

PDQ-39 subdomain	Asian patients (n = 173)		Caucasian patients (n = 371)	
	Placebo (n = 85)	Safinamide (n = 88)	Placebo (n = 188)	Safinamide (n = 183)
Mobility				
Mean at baseline (SE)	31.06 (2.40)	31.90 (2.40)	38.38 (1.76)	36.99 (1.74)
LS mean (SE)	4.65 (4.98)	-1.58 (4.73)	-0.97 (1.11)	-5.29 (1.13)
LS difference vs. placebo (95% CI)	-6.24 (-10.86, -1.62)		-4.32 (-7.22, -1.43)	
p-value	0.0084		0.0035	
ADL				
Mean at baseline (SE)	26.42 (1.97)	29.21 (2.32)	34.19 (1.65)	34.77 (1.66)
LS mean (SE)	-1.87 (5.56)	-7.72 (5.28)	-0.78 (1.17)	-4.98 (1.18)
LS difference vs. placebo (95% CI)	-5.85 (-11.03, -0.66)		-4.19 (-7.22, -1.16)	
p-value	0.0273		0.0068	
Emotional well-being				
Mean at baseline (SE)	24.31 (2.11)	22.49 (1.99)	28.60 (1.38)	28.83 (1.48)
LS mean (SE)	-1.05 (5.34)	-2.07 (5.08)	-1.45 (0.98)	-4.54 (0.99)
LS difference vs. placebo (95% CI)	-1.01 (-5.99, 3.96)		-3.09 (-5.64, -0.53)	
p-value	0.6879 (NS)		0.0180	
Stigma				
Mean at baseline (SE)	21.32 (2.36)	24.86 (2.52)	25.47 (1.72)	26.30 (1.78)
LS mean (SE)	-0.80 (6.09)	-2.09 (5.76)	-1.78 (1.18)	-3.66 (1.19)
LS difference vs. placebo (95% CI)	-1.29 (-6.94, 4.36)		-1.88 (-4.94, 1.18)	
p-value	0.6532 (NS)		0.2283 (NS)	
Social support				
Mean at baseline (SE)	12.60 (2.01)	12.88 (1.84)	15.88 (1.49)	14.87 (1.35)
LS mean (SE)	-7.35 (4.82)	-6.76 (4.57)	1.27 (1.27)	-0.09 (1.28)
LS difference vs. placebo (95% CI)	0.60 (-3.88, 5.07)		-1.36 (-4.66, 1.94)	
p-value	0.7922 (NS)		0.4187 (NS)	
Cognitive impairment				
Mean at baseline (SE)	24.19 (2.04)	23.72 (1.92)	26.11 (1.26)	27.46 (1.35)
LS mean (SE)	2.79 (4.65)	4.50 (4.42)	-1.35 (0.92)	-1.45 (0.93)
LS difference vs. placebo (95% CI)	1.71 (-2.61, 6.02)		-0.10 (-2.49, 2.28)	
p-value	0.4358 (NS)		0.9317 (NS)	
Communication				
Mean at baseline (SE)	18.04 (1.95)	19.22 (2.08)	23.68 (1.42)	23.36 (1.52)
LS mean (SE)	1.62 (5.53)	-1.22 (5.25)	-1.27 (1.08)	-1.10 (1.09)
LS difference vs. placebo (95% CI)	-2.84 (-7.99, 2.31)		0.17 (-2.63, 2.98)	
p-value	0.2776 (NS)		0.9038 (NS)	
Bodily discomfort				
Mean at baseline (SE)	27.35 (2.24)	30.78 (2.31)	36.94 (1.57)	38.71 (1.72)
LS mean (SE)	11.89 (5.78)	8.07 (5.50)	-0.90 (1.29)	-4.85 (1.30)
LS difference vs. placebo (95% CI)	-3.82 (-9.22, 1.57)		-3.95 (-7.31, -0.59)	
p-value	0.1633 (NS)		0.0213	
Summary index				
Mean at baseline (SE)	23.16 (1.54)	24.38 (1.50)	28.55 (1.09)	28.91 (1.09)
LS mean (SE)	1.54 (3.77)	-0.98 (3.58)	-0.97 (0.70)	-3.32 (0.71)
LS difference vs. placebo (95% CI)	-2.51 (-6.03, 1.00)		-2.34 (-4.17, -0.52)	
p-value	0.1592 (NS)		0.0121	

ADL, activities of daily living; CI, confidence interval; LS, least squares; NS, not significant; PDQ-39, 39Item Parkinson Disease Questionnaire; SE, standard error.